Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Clinical Trials Research Unit celebrates five years of running and supporting excellent clinical trials that benefit patients and improve healthcare.

On 6 December 2017, the Oxford Clinical Trials Research Unit (OCTRU) celebrated five years of highlights and successes. OCTRU gives trials access to a robust quality assurance framework, a training programme for all members of a trials team, IT infrastructure to support efficient trials, and a skilled team of statisticians. The result? OCTRU has been assessed as one of the best performing academic clinical trials units in the UK for three years in a row. 

OCTRU is well-placed to lead the way in creativity, innovation and excellence
Professor Sallie Lamb

OCTRU is the result of a collaboration between six existing Oxford clinical trials units. The central OCTRU ‘hub’  based at NDORMS supports teams in five speciality themes, focusing on cancer, trauma, rehabilitation, rheumatology, and surgery research.

Just how good are the clinical trials here at the University of Oxford? Dr Ben Goldacre of the EBM DataLab, who gave an invited lecture on the state of trials across the UK and beyond, confirmed that we’re doing rather well. The University of Oxford consistently appears in the upper ranks of Dr Goldacre’s Trials Trackers, which measure elements of good trial conduct such as trial registration and publishing the trial results.

Good conduct is great, but it isn’t enough. As Professor Matt Costa of the OCTRU trauma trials theme said: “Our trials need to change clinical practice. They need to benefit patients.”

Each element of OCTRU is achieving just that. For example, the statistician team has developed skills in adaptive trials, which allow trials to be stopped early for lack of efficacy or high toxicity. Participants do not join a trial destined to show no efficacy, saving their time. The trauma team’s DRAFFT trial has changed the way surgeons deal with wrist fractures and has already saved the NHS £2 million. And the cancer team focuses on cancers of unmet need, looking at treatments for rare cancers that affect small groups of patients.

With over £31 million in funded trials in just five years, OCTRU has proven the success of its integrative support model for clinical trials. Director Professor Sallie Lamb said: “We have laid the foundation of an excellent infrastructure and collegiate working environment. I am immensely proud and impressed by the achievements of everyone working in OCTRU. Trials are challenging to design and complete, but I have no doubt that OCTRU is well-placed to lead the way in creativity, innovation and excellence.”

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Kennedy Main Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

A more tailored approach to treating psoriatic arthritis

Arthritis Botnar Funding Main

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

Motion-capture to help children walk: Oxford team support new gait laboratory in Ethiopia

Main Orthopaedics and trauma

The Research at Oxford on Analysis of Motion (ROAM) team at the University of Oxford have supported CURE Ethiopia Children’s Hospital to develop and open a brand new gait laboratory, the first of its kind in the country and the only other active gait lab on the African continent outside of South Africa.

Professor Eleanor Stride recognised in New Year’s Honours list 2021

Awards Main

Statutory Professor of Biomaterials is awarded Officer of the Order of the British Empire (OBE) for services to Engineering

Drug may boost vaccine responses in older adults

Kennedy Main

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Kennedy Main Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.